INTRODUCTION
A nkylosing spondylitis (AS) is a chronic inflammatory disease that affects the axial skeleton, often beginning in the sacroiliac joints, but accompanied also by other signs, including enthesitis, lung fibrosis and eye involvement. AS generally occurs in the second or third decade of life with inflammatory low back pain and has a strong relation with HLA-B27. The objective of the treatment until the end of the 90's was to ameliorate pain and stiffness and preserve function (1) . Nonselective nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors, and nonpharmalogic interventions, such as physiotherapy, exercise, education, and lifestyle modifications were the basis of the management. Therapy with agents like sulphasalazine was administered for peripheral arthritis (1, 2). 
Acute toxoplasmosis infection in a patient

DISCUSSION
TG is an obligate intracellular parasite that infects up to a third of the world's population. Infection is mainly acquired by ingestion of food or water that is contaminated with oocysts shed by cats or by eating undercooked or raw meat containing tissue cysts. Primary infection is usually subclinical, but in some patients cervical lymphadenopathy, ocular disease, encephalitis, myocarditis, and pneumonitis can be present. By contrast with the favourable course of toxoplasmosis in almost all immunocompetent individuals, the disease can be lifethreatening in the immunocompromised ones. Toxoplasmic chorioretinitis, a common presentation in these individuals, may be seen in the setting of congenital or postnatally acquired disease as a result of acute infection or reactivation (4). Another severe presentation is the central nervous system involvement, classically described in the setting of AIDS (5) and also in the presence of corticosteroids and anti-TNF-alpha therapy (6, 7) . Adalimumab was the first fully human monoclonal antibody targeted against TNF-alpha. As other anti-TNF-alpha agents (etanercept and infliximab), it is licensed for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (8) . TNF inhibition has demonstrated effectiveness in the treatment of AS symptoms and all currently available anti-TNF agents appear to have similar efficacy (9) . More than 300.000 patients worldwide have been treated with adalimumab, which is commercially available in the US and 62 other countries (10), and so far, seems to be safe (11) . Anti-TNF-alpha agents can cause infections, malignancies, injection site reactions and others (11) (12) (13) (14) . Tuberculosis is the most frequent opportunistic infection which has been reported with anti-TNF-alpha therapy (8, 11) . We found a small number of reported cases of toxoplasmosis in patients using anti-TNF therapy: two cases of chorioretinitis (15) and two cases of cerebral toxoplasmosis (6, 7) . Based on those cases, Lassoued et al raised the question of a link between toxoplasmosis infection and TNF-alpha antagonists therapy (15) . We did not found any description of acute toxoplasmosis in patients using adalimumab. TNF-alpha plays an important role not only in inflammatory process, but also in the normal response against infections, and as a consequence, blocking this cytokine may increase risk of infectious complications (8) . It is known that TNF-alpha has an important role specifically in protection against TG infections , playing a sinergycal role with IFN-gamma (16) . A study conducted by Chang et al revealed that mice treated for 8 days with recombinant murine TNF during infection with a virulent strain of TG were protected against the infection (16) . In 1992, Johnson demonstrated that mice infected with a nonvirulent strain of TG developed infection and higher mortality when TNF-neutralizing antibod-ies were administrated. Although these evidences confirm that TNF is an important mediator of resistance to TG (17) , there are few reported cases of toxopasmosis or other opportunistic infections in patients treated with anti-TNF-alpha therapy and specifically with adalimumab (6, 7, 11, 15) . TG infection has a wide range of manifestations, and its diagnosis can be difficult. General symptoms like malaise, low-grade fever and visual complaints should prompt the investigation towards TG epidemiological and serological parameters. In this setting, an acute form of the disease or its reactivation could be present. In addition, we suggest that adalimumab can be safely reintroduced after the complete resolution of an acute TG infection.
